We report on the auxological and endocrine evolution of 28 patients presenting with Prader-Willi syndrome. Half of them received growth hormone (GH) therapy (group 2). The spontaneous auxological evolution was analyzed in the two groups from 2 to 8 years; the mean SDS for height remained stable (–0.6 ± 0.6) in group 1 and decreased (from –2.0 ± 0.9 to –2.7 ± 0.6) in group 2. Magnetic resonance imaging showed marked pituitary hypoplasia in the two groups. In group 2, the mean GH peak after two provocative tests was 3.8 ± 2.4 µg/l, the mean SDS values for insulin-like growth factor I levels were –2.0 ± 1.5 (range from –0.5 to –5.0). The mean duration of GH treatment was 3.6 ± 2.9 (range 1–9.3) years. 14 children completed 1 year of treatment. The two groups had opposite evolutions in ΔSDS for height (–0.8 ± 0.8 vs. +1.1 ± 0.8), for growth velocity (–1.9 ± 2.2 vs. +2.9 ± 2.7), and for Z score of the body mass index (+0.37 ± 1.3 vs. –0.14 ± 0.76; group 1 vs. group 2). This retrospective study shows that, in children with Prader-Willi syndrome and true GH deficiency, long-term GH therapy is effective in increasing growth velocity and in maintaining body mass index.

1.
Prader A, Labhart A, Willi H: Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchidismus und Oligophrenie nach myotonieartigem Zustand im Neugeborenenalter. Schweiz Med Wochenschr 1956;86:1260–1261.
2.
Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F: Prader-Willi syndrome: Consensus diagnostic criteria. Pediatrics 1993;91:398–402.
3.
Donaldson MDC, Chu LE, Cooke A, Wilson A, Greene SA, Stephenson JBP: The Prader-Willi syndrome. Arch Dis Child 1994;70:58–63.
4.
Webb T, Clarke D, Hardy CA, Kilpatrick MW, Corbett J, Dahlitz M: A clinical, cytogenetic, and molecular study of 40 adults with the Prader-Willi syndrome. J Med Genet 1995;32:181–185.
5.
Chu CE, Looke A, Stephenson JBP, Tolmie JL, Clarke B, Parry-Jones WL, Connor JM, Donaldson MDL: Diagnosis in Prader-Willi syndrome. Arch Dis Child 1994;71:441–442.
6.
Dittrich B, Buiting K, Korn B, Rickard S, Buxton J, Saitoh S, Nicholls RD, Poustka A, Winterpacht A, Zabel B, Horsthemke B: Imprint switching on human chromosome 15 may involve alternative transcripts of the SNRPN gene. Nat Genet 1996;14:163–170.
7.
Greenswag LR: Adults with Prader-Willi syndrome: A survey of 232 cases. Dev Med Child Neurol 1987;29:145–152.
8.
Swaab DF: Prader-Willi syndrome and the hypothalamus. Acta Paediatr 1997;86(suppl 423):50–54.
9.
Costeff H, Holm VA, Ruvalcaba R, Shaver J: Growth hormone secretion in Prader-Willi syndrome. Acta Paediatr Scand 1990;79:1059–1062.
10.
Michel G, Chaussain JL, Lob JC: Les explorations endocriniennes dans le syndrome de Prader, Labhart et Willi. Arch Fr Pédiatr 1976;33:467–476.
11.
Butler MG, Meaney FJ: Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics 1991;88:853–859.
12.
Wollmann HA, Schultz U, Grauer ML, Ranke MB: References values for height and weight in Prader-Willi syndrome based on 315 patients. Eur J Pediatr 1998;157:634–642.
13.
Angulo M, Castro-Magana M, Mazur B, Canas JA, Vitollo PM, Sarrantino M: Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab 1996;9:393–400.
14.
Lee PDK, Hwu K, Henson H, Brown , Brickler JT, Leblanc AD, Firotto ML, Greenberg F, Klish WJ: Body composition study in Prader-Willi syndrome; in Ellis KJ, Eastmann JD (eds): Effects of Growth Hormone Therapy on Human Body Composition. New York, Plenum Press, 1993.
15.
Bosio L, Beccaria L, Benzi F, Sanzari A, Chiumello G: Body composition during GH treatment in Prader-Labhardt-Willi syndrome. J Pediatr Endocrinol Metab 1999;12:351–353.
16.
Lindgren AC, Hagenas L, Muller J, Blichfeldt S, Rosenboerg M, Brismar T, Ritzen EM: Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome. Acta Paediatr 1997;86(suppl 423):60–62.
17.
Hauffa BP: One-year results of growth hormone treatment of short stature in Prader-Willi syndrome. Acta Paediatr 1997;86(suppl 423):63–65.
18.
Eiholzer U, Weber, R, Stutz K, Steiger H: Effect of 6 months of growth hormone treatment in young children with Prader-Willi syndrome. Acta Paediatr 1997;86(suppl 423):66–68.
19.
Lindgren AC, Hagenas L, Müller J, Blichfeldt S, Rosenboerg M, Brismar T, Ritzen EM: Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Pediatr 1998;87:28–32.
20.
Carrel A, Myers SE, Whitman BY, Allen DB: Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr 1999;134:215–221.
21.
Chatelain PG, Van Wyck JJ, Copeland KC, Blethen SL, Underwood LE: Effects of in vitro action of serum protease or exposure to acid on measurable immunoreactive somatomedin C in serum. J Clin Endocrinol Metab 1983;56:376–381.
22.
Sempé M, Pédron G, Roy-Pernot M: Auxologie: méthode et séquences. Paris, Théraplix, 1979.
23.
Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A: Body mass index variations: Centiles from birth to 87 years. Eur J Clin Nutr 1991;45:13–21.
24.
Argyropoulou M, Pérignon F, Brunelle F, Brauner R, Rappaport R: Height of normal pituitary gland as a function of age evaluated by magnetic resonance imaging in children. Pediatr Radiol 1991;21:247–249.
25.
Grugni G, Guzzaroni G, Bettio P, Ardizzi A, Calo G, Morabito F: Neuroradiological study of the hypothalamic pituitary region in the Prader-Willi syndrome. 35th Annu Meet of the ESPE. Horm Res 1996;46:27.
26.
Miller L, Angulo M, Price D, Taneja S: MR of the pituitary in patients with Prader-Willi syndrome: Size determination and imaging findings. Pediatr Radiol 1996;26:43–47.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.